Professor Martin R Wilkins

Publications


Journals

  • Nasim MT; Ogo T; Ahmed M; Randall R; Chowdhury HM; Snape KM; Bradshaw TY; Southgate L; et alLee GJ; Jackson I; Lord GM; Gibbs JS; Wilkins MR; Ohta-Ogo K; Nakamura K; Girerd B; Coulet F; Soubrier F; Humbert M; Morrell NW; Trembath RC; Machado RD. (Dec 2011). Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Hum Mutat. 32:1385-1389. DOI.
  • Schermuly RT; Ghofrani HA; Wilkins MR; Grimminger F. (Aug 2011). Mechanisms of disease: pulmonary arterial hypertension. NAT REV CARDIOL. 8:443-455. DOI.
  • Rhodes CJ; Howard LS; Busbridge M; Ashby D; Kondili E; Gibbs JS; Wharton J; Wilkins MR. (12 Jul 2011). Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol. 58:300-309. DOI.
  • Rhodes CJ; Wharton J; Howard LS; Gibbs JS; Wilkins MR. (Jul 2011). Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. Heart. 97:1054-1060. DOI.
  • Zhai Z; Murphy K; Tighe H; Wang C; Wilkins MR; Gibbs JS; Howard LS. (Nov 2011). Differences in ventilatory inefficiency between pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Chest. 140:1284-1291. DOI.
  • Rhodes CJ; Wharton J; Howard L; Gibbs JS; Vonk-Noordegraaf A; Wilkins MR. (Dec 2011). Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target. Eur Respir J. 38:1453-1460. DOI.
  • Robbins IM; Hemnes AR; Gibbs JS; Christman BW; Howard L; Meehan S; Cabrita I; Gonzalez R; et alOyler T; Zhao L; Du RH; Mendes LA; Wilkins MR. (Feb 2011). Safety of sapropterin dihydrochloride (6r-bh4) in patients with pulmonary hypertension. EXP LUNG RES. 37:26-34. DOI.
  • Abdul-Salam VB; Wharton J; Cupitt J; Berryman M; Edwards RJ; Wilkins MR. (16 Nov 2010). Proteomic analysis of lung tissues from patients with pulmonary arterial hypertension. Circulation. 122:2058-2067. DOI.
  • Wilkins MR; Ali O; Bradlow W; Wharton J; Taegtmeyer A; Rhodes CJ; Ghofrani HA; Howard L; et alNihoyannopoulos P; Mohiaddin RH; Gibbs JS; Simvastatin Pulmonary Hypertension Trial (SiPHT) Study Group. (15 May 2010). Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med. 181:1106-1113. DOI.
  • Archer SL; Weir EK; Wilkins MR. (11 May 2010). Basic Science of Pulmonary Arterial Hypertension for Clinicians New Concepts and Experimental Therapies. CIRCULATION. 121:2045-U175. DOI.
  • Francis BN; Wilkins MR; Zhao L. (Aug 2010). Tetrahydrobiopterin and the regulation of hypoxic pulmonary vasoconstriction. Eur Respir J. 36:323-330. DOI.
  • Diller GP; Thum T; Wilkins MR; Wharton J. (Jan 2010). Endothelial Progenitor Cells in Pulmonary Arterial Hypertension. TRENDS CARDIOVAS MED. 20:22-29.
  • Stavros F; Kramer WG; Wilkins MR. (Jan 2010). The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects. British Journal of Clinical Pharmacology. 69:23-26.
  • Tzoulaki I; Molokhia M; Curcin V; Little MP; Millet CJ; Hughes RI; Khunti K; Wilkins MR; et alMajeed A; Elliott P. (3 Dec 2009). Cardiovascular outcomes in type 2 diabetes patients exposed to thiazolidinediones and other oral anti-diabetic treatment: a population based analysis. British Medical Journal. 339. DOI.
  • Zhao L; Sebkhi A; Ali O; Wojciak-Stothard B; Mamanova L; Yang Q; Wharton J; Wilkins MR. (Oct 2009). Simvastatin and sildenafil combine to attenuate pulmonary hypertension. EUR RESPIR J. 34:948-957. DOI.
  • Wilkins MR; Zhao L. (11 Aug 2009). [Future treatment of pulmonary arterial hypertension]. Zhonghua Yi Xue Za Zhi. 89:2097-2098.
  • Rhodes CJ; Davidson A; Gibbs JS; Wharton J; Wilkins MR. (Jan 2009). Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther. 121:69-88. DOI.
  • Baliga RS; Zhao L; Madhani M; Lopez-Torondel B; Visintin C; Selwood D; Wilkins MR; MacAllister RJ; et alHobbs AJ. (15 Oct 2008). Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. AM J RESP CRIT CARE. 178:861-869. DOI.
  • Michelakis ED; Wilkins MR; Rabinovitch M. (30 Sep 2008). Emerging concepts and translational priorities in pulmonary arterial hypertension. CIRCULATION. 118:1486-1495. DOI.
  • Nickel N; Kempf T; Tapken H; Tongers J; Laenger F; Lehmann U; Golpon H; Olsson K; et alWilkins MR; Gibbs JSR; Hoeper MM; Wollert KC. (1 Sep 2008). Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. AM J RESP CRIT CARE. 178:534-541. DOI.
  • Wilkins MR; Wharton J; Grimminger F; Ghofrani HA. (Jul 2008). Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J. 32:198-209. DOI.
  • Diller GP; van Eijl S; Okonko DO; Howard LS; Ali O; Thum T; Wort SJ; Bedard E; et alGibbs JSR; Bauersachs J; Hobbs AJ; Wilkins MR; Gatzoulis MA; Wharton J. (10 Jun 2008). Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. CIRCULATION. 117:3020-3030. DOI.
  • Ali O; Wharton J; Gibbs JS; Howard L; Wilkins MR. (Jun 2007). Emerging therapies for pulmonary arterial hypertension. Expert Opin Investig Drugs. 16:803-818. DOI.
  • Kojonazarov BK; Imanov BZ; Amatov TA; Mirrakhimov MM; Naeije R; Wilkins MR; Aldashev AA. (Feb 2007). Noninvasive and invasive evaluation of pulmonary arterial pressure in highlanders. Eur Respir J. 29:352-356. DOI.
  • Kalmyrzaev B; Aldashev A; Khalmatov M; Polupanov A; Jumagulova A; Mamanova L; Wilkins MR; Town M. (Sep 2006). A Genome-Wide Scan for Premature Hypertension Supports Linkage to Chromosome 2 in a Large Kyrgyz Family. Hypertension. 48:908-913. DOI.
  • Abdul-Salam VB; Paul GA; Ali JO; Gibbs SR; Rahman D; Taylor GW; Wilkins MR; Edwards RJ. (Apr 2006). Identification of plasma protein biomarkers associated with idiopathic pulmonary arterial hypertension. Proteomics. 6:2286-2294. DOI.
  • Machado RD; Koehler R; Glissmeyer E; Veal C; Suntharalingam J; Kim M; Carlquist J; Town M; et alElliott CG; Hoeper M; Fijalkowska A; Kurzyna M; Thomson JR; Gibbs SR; Wilkins MR; Seeger W; Morrell NW; Gruenig E; Trembath RC; Janssen B. (1 Apr 2006). Genetic association of the serotonin transporter in pulmonary arterial hypertension. AM J RESP CRIT CARE. 173:793-797. DOI.
  • Aldashev AA; Kojonazarov BK; Amatov TA; Sooronbaev TM; Mirrakhimov MM; Morrell NW; Wharton J; Wilkins MR. (Aug 2005). Phosphodiesterase type 5 and high altitude pulmonary hypertension. THORAX. 60:683-687. DOI.
  • Paul GA; Gibbs JS; Boobis AR; Abbas A; Wilkins MR. (Jul 2005). Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol. 60:107-112. DOI.
  • Wharton J; Strange JW; Møller GM; Growcott EJ; Ren X; Franklyn AP; Phillips SC; Wilkins MR. (1 Jul 2005). Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med. 172:105-113. DOI.
  • Wilkins MR; Paul GA; Strange JW; Tunariu N; Gin-Sing W; Banya WA; Westwood MA; Stefanidis A; et alNg LL; Pennell DJ; Mohiaddin RH; Nihoyannopoulos P; Gibbs JS. (1 Jun 2005). Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med. 171:1292-1297. DOI.
  • Khoo JP; Zhao L; Alp NJ; Bendall JK; Nicoli T; Rockett K; Wilkins MR; Channon KM. (26 Apr 2005). Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. CIRCULATION. 111:2126-2133. DOI.
  • Phillips PG; Long L; Wilkins MR; Morrell NW. (Jan 2005). cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol. 288:L103-L115. DOI.
  • Wilkins MR. (15 Feb 2004). Selective or nonselective endothelin receptor blockade in pulmonary arterial hypertension. Am J Respir Crit Care Med. 169:433-434. DOI.
  • Sebkhi A; Strange JW; Phillips SC; Wharton J; Wilkins MR. (1 Jul 2003). Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation. 107:3230-3235. DOI.
  • Gibbs JS; Wharton J; Wilkins MR. (Feb 2003). Pulmonary arterial hypertension and the vasoconstrictive factor: is there still a role for vasodilator testing?. Eur Heart J. 24:297-298.
  • Zhao L; Mason NA; Strange JW; Walker H; Wilkins MR. (21 Jan 2003). Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic peptide activity. CIRCULATION. 107:234-237. DOI.
  • Aldashev AA; Sarybaev AS; Sydykov AS; Kalmyrzaev BB; Kim EV; Mamanova LB; Maripov R; Kojonazarov BK; et alMirrakhimov MM; Wilkins MR; Morrell NW. (15 Nov 2002). Characterization of high-altitude pulmonary hypertension in the Kyrgyz: association with angiotensin-converting enzyme genotype. Am J Respir Crit Care Med. 166:1396-1402. DOI.
  • Rabiner EA; Gunn RN; Wilkins MR; Sedman E; Grasby PM. (Sep 2002). Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11C]WAY-100635 and [11C]raclopride. J Psychopharmacol. 16:195-199.
  • Wilkins MR; Møller GM; Ren X; Wharton J. (Jun 2002). Developments in therapeutics for pulmonary arterial hypertension. Minerva Cardioangiol. 50:175-187.
  • Rabiner EA; Wilkins MR; Turkheimer F; Gunn RN; Udo de Haes J; de Vries M; Grasby PM. (Jun 2002). 5-Hydroxytryptamine1A receptor occupancy by novel full antagonist 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzdioxyn-5-yl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3-(2H)-one-1,1-dioxide: a[11C][O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide trihydrochloride (WAY-100635) positron emission tomography study in humans. J Pharmacol Exp Ther. 301:1144-1150.
  • Wilkins MR; Aldashev A; Morrell NW. (4 May 2002). Nitric oxide, phosphodiesterase inhibition, and adaptation to hypoxic conditions. Lancet. 359:1539-1540.
  • King L; Wilkins MR. (Apr 2002). Natriuretic peptide receptors and the heart. Heart. 87:314-315.
  • Strange JW; Wharton J; Phillips PG; Wilkins MR. (Mar 2002). Recent insights into the pathogenesis and therapeutics of pulmonary hypertension. Clin Sci (Lond). 102:253-268.
  • Wilkins MR. (28 Feb 2002). What do we want from proteomics in the detection and avoidance of adverse drug reactions. Toxicol Lett. 127:245-249.
  • Wilkins MR; Wharton J. (Dec 2001). Progress in, and future prospects for, the treatment of primary pulmonary hypertension. Heart. 86:603-604.
  • Zhao L; Mason NA; Morrell NW; Kojonazarov B; Sadykov A; Maripov A; Mirrakhimov MM; Aldashev A; et alWilkins MR. (24 Jul 2001). Sildenafil inhibits hypoxia-induced pulmonary hypertension. CIRCULATION. 104:424-428.
  • Jourdan KB; Mason NA; Long L; Philips PG; Wilkins MR; Morrell NW. (Jun 2001). Characterization of adenylyl cyclase isoforms in rat peripheral pulmonary arteries. Am J Physiol Lung Cell Mol Physiol. 280:L1359-L1369.
  • Morrell NW; Wilkins MR. (Mar 2001). Genetic and molecular mechanisms of pulmonary hypertension. Clin Med. 1:138-145.
  • Zhao L; Sebkhi A; Nunez DJR; Long L; Haley CS; Szpirer J; Szpirer C; Williams AJ; et alWilkins MR. (23 Jan 2001). Right ventricular hypertrophy secondary to pulmonary hypertension is linked to rat chromosome 17 - Evaluation of cardiac ryanodine Ryr2 receptor as a candidate. CIRCULATION. 103:442-447.
  • Wilkins MR; Gibbs JS; Shovlin CL. (7 Oct 2000). A gene for primary pulmonary hypertension. Lancet. 356:1207-1208.
  • Rabiner EA; Gunn RN; Wilkins MR; Sargent PA; Mocaer E; Sedman E; Cowen PJ; Grasby PM. (Jul 2000). Drug action at the 5-HT1A receptor in vivo: Autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-11C]WAY-100635. Nuclear Medicine and Biology. 27:509-513. DOI.
  • Aguirre JI; Morrell NW; Long L; Clift P; Upton PD; Polak JM; Wilkins MR. (May 2000). Vascular remodeling and ET-1 expression in rat strains with different responses to chronic hypoxia. Am J Physiol Lung Cell Mol Physiol. 278:L981-L987.
  • Zhao L; Long L; Morrell NW; Wilkins MR. (9 Feb 1999). NPR-A-Deficient mice show increased susceptibility to hypoxia-induced pulmonary hypertension. Circulation. 99:605-607.
  • Sebkhi A; Zhao L; Nunez DR; Haley C; Wilkins MR. (1999). Genetic determination of cardiac mass in normotensive rats: results from an F344 x WKY cross. Hypertension. 33:949-953.
  • Redondo J; Bishop JE; Wilkins MR. (May 1998). Effect of atrial natriuretic peptide and cyclic GMP phosphodiesterase inhibition on collagen synthesis by adult cardiac fibroblasts. British Journal of Pharmacology. 124:1455-1462. DOI.
  • Brown LA; RAD R; Nunez DJ; Wharton J; Lowe DG; Wilkins MR. (Jun 1997). Downregulation of natriuretic peptide C-receptor protein in the hypertrophied ventricle of the aortovenocaval fistula rat. 36:363-371.
  • Viskoper RJ; PJLM B; Schelling A; Ribeiro AB; Kantola IM; Wilkins MR; Kobrin I. (Jun 1997). A randomised, double-blind trial comparing mibefradil and amlodipine: Two long-acting calcium antagonists with similar efficacy but different tolerability profiles. Journal of Human Hypertension. 11:387-393.
  • Clifford CP; Adams DA; Murray S; Taylor GW; Wilkins MR; Boobis AR; Davies DS. (Feb 1997). The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. European Journal of Clinical Pharmacology. 52:311-315. DOI.
  • Zhao L; Al-Tubuly R; Sebkhi A; Owji AA; DJR N; Wilkins MR. (Nov 1996). Angiotensin II receptor expression and inhibition in the chronically hypoxic rat lung. British Journal of Pharmacology. 119:1217-1222.
  • Zhao L; Brown LA; Owji AA; Nunez DJ; Smith DM; Ghatei MA; Bloom SR; Wilkins MR. (Aug 1996). Adrenomedullin activity in chronically hypoxic rat lungs. Am J Physiol. 271:H622-H629.
  • Kirk JE; Wilkins. (1996). Renal effects of concurrent E-24.11 and ACE inhibition in the aortovenocaval fistula rat. 119:943-948.
  • Brown LA; Nunez DJ; CIO B; Wilkins MR. (Jun 1995). Selective increase in endothelin-1 and endothelin-A receptor subtype during cardiac hypertrophy in the rat. Cardiovascular Research. 29:768-774.
  • Good JM; Peters M; Wilkins MR; Jackson N; Oakley CM; Cleland JG. (May 1995). Renal response to candoxatrilat in patients with heart failure. Journal of the American College of Cardiology. 25:1273-1281.
  • Hirokawa K; O'Shaughnessy KM; Ramrakha P; Wilkins MR. (Dec 1994). Inhibition of nitric oxide synthase in vascular smooth muscle by retinoids. British Journal of Pharmacology. 113:1448-1454.
  • RAD R; Matsuda Y; Wilkins MR; Polak JM; Wharton J. (Nov 1994). Identification of renal natriuretic peptide receptor subpopulations by use of the non-peptide antagonist, HS-142-1. British Journal of Pharmacology. 113:931-939.
  • Hirokawa K; O'Shaughnessy K; Moore K; Ramrakha P; Wilkins MR. (Jun 1994). Induction of nitric oxide synthase in cultured vascular smooth muscle cells: the role of cyclic AMP. British Journal of Pharmacology. 112:396-402.
  • Brown LA; Nunez DJ; Wilkins MR. (Dec 1993). Differential regulation of natriuretic peptide receptor mRNAs during the development of cardiac hypertrophy in the rat. Journal of Clinical Investigation. 92:2702-2712.
  • Kirk JE; Wilkins MR. (Sep 1993). Effect of endopeptidase-24.11 inhibition and atrial natriuretic peptide clearance receptor ligand on the response to rat brain natriuretic peptide in the conscious rat. British Journal of Pharmacology. 110:350-354.
  • Clesham CJ; Kennedy A; Lavender JP; Dollery CT; Wilkins MR. (Aug 1993). Meta-iodobenzylguanidine (MIBG) scanning in the diagnosis of phaeochromocytoma. Journal of Human Hypertension. 7:353-356.
  • Ligueros M; Unwin RJ; Wilkins MR; Humphreys J; Coles SJ; JGF C. (Dec 1992). A comparison of the effects of the selective a-blocker terazosin with the selective b1-blocker atenolol on blood pressure control, serum lipids and exercise performance in mild-to-moderate hypertension. Clinical Autonomic Research. 2:373-381.
  • Wilkins MR; Settle SL; Kirk JE; Taylor SA; Moore KP; Unwin RJ. (Sep 1992). Response to atrial natriuretic peptide, endopeptidase-24.11 inhibition and C-ANP receptor ligand in the rat. British Journal of Pharmacology. 107:50-57.
  • Yan Q; Settle SL; Wilkins MR. (Jun 1991). Hypotension induced by intravascular administration of nerve growth factor in the rat. Clinical Science. 80:565-569.
  • Greenwald JE; Needleman P; Wilkins MR; Schreiner GF. (1991). Renal atriopeptin synthesis in rats in physiology and pathophysiology. American Journal of Physiology. 260:602-607.
  • Toki Y; Ito T; Shiono S; Siegel NR; Gierse JK; Wilkins MR; Needleman P. (Jul 1990). Alternative mechanisms for atriopeptin prohormone processing by isolated perfused rat hearts. Journal of Pharmacology & Experimental Therapeutics. 254:228-235.
  • Wilkins MR; Settle SL; Needleman P. (Apr 1990). Augmentation of the natriuretic activity of exogenous and endogenous atriopeptin in rats by inhibition of guanosine 3', 5'-cyclic GMP monophosphate degradation. Journal of Clinical Investigation. 85:1274-1279. DOI.
  • Wilkins MR; Settle SL; Stockmann PT; Needleman P. (1990). Maximizing the natriuretic effect of endogenous atriopeptin in a rat model of heart failure. Proceedings of the National Academy of Sciences USA. 87:6465-6469.
  • Lewis HM; Wilkins MR; Kendall MJ; Lee MR. (Sep 1989). Carbidopa does not affect the renal response to atrial natriuretic factor in man. Clinical Science. 73:281-285.
  • Lewis HM; Ratcliff WR; RAW S; Wilkins MR; Bayliss PH. (1989). Development and validation of a two-site immunometric assay for human atrial natriuretic factor in unextracted plasma. Clinical Chemistry. 35.
  • Wilkins MR; Gammage MD; Lewis HM; Tan LB; Weissberg PL. (Apr 1988). Effect of lower-body positive-pressure on blood pressure, plasma atrial natriuretic factor concentration, sodium and water excretion in healthy volunteers and cardiac transplant recipients. Cardiovascular Research. 22:231-235.
  • Lewis HM; Wilkins MR; Selwyn BM; Yellard VJ; Griffith ME; Bhoola KD. (1988). Urinary cyclic GMP but not tissue kallikrein follows the plasma atrial natriuretic factor (ANF) response to acute volume expansion with saline. Clinical Science. 75:489-494.
  • Wilkins MR; Lewis HM; West MJ; Kendall MJ; Lote CJ. (Jun 1987). Captopril reduces the renal responses to intravenous atrial natriuretic peptide in normotensives. Journal of Human Hypertension. 1:47-51.
  • Beerahee M; Wilkins MR; Jack DB; Beevers DG; Kendall MJ. (1987). Twelve hour (tough) plasma nifedipine concentrations during chronic treatment with nifedipine retard. European Journal of Clinical Pharmacology. 32:347-349.
  • Smith SR; Kendall MJ; Lobo J; Beerahee A; Jack DB; Wilkins MR. (1987). Ranitidine and cimetidine; drug interactions with single dose and steady-state nifedipine administration. British Journal of Clinical Pharmacology. 23:311-315.
  • Smith SR; Wilkins MR; Jack DB; Kendall MJ; Laugher S. (Sep 1986). Pharmacokinetics interactions between felodipine and metoprolol. European Journal of Clinical Pharmacology. 31:575-578. DOI.
  • Wilkins MR; Gammage MD; Tan LB; Kendall MJ; Weissberg PL; Littler WA. (1986). Effects of lower-body positive-pressure on atrial dimension and plasma atrial natriuretic peptide concentration. Journal of Hypertension. 4:500-502.
  • Wilkins MR; Wood JA; Adu D; Lote CJ; Kendall MJ; Michael J. (1986). Change in plasma immunoreactive atrial natriuretic peptide during sequential ultrafiltration and haemodialysis. Clinical Science. 71:157-160.
  • Wilkins MR; Gove RI; Roberts SD; Kendall MJ. (1986). Behcet's disease presenting as benign intracranial hypertension. Postgraduate Medical Journal. 62:39-41.
  • Wilkins MR; Jennings PE; West MJ; Kendall MJ; Barnett AH. (Dec 1985). Dissociation of changes in sodium transport in erythrocytes from changes in blood pressure. Journal of Hypertension. 3:21-23.
  • Wilkins MR; Kendall MJ. (Nov 1985). Stroke affecting young men after alcoholic binges. British Medical Journal. 291:1342-1343.
  • Wilkins MR; Wynne R; Kendall MJ. (Jun 1985). A placebo controlled comparison of the effects of pirenzepine and amitriptyline on the tyramine pressor test. British Journal of Clinical Pharmacology. 19:829-831.
  • Jack DB; Wilkins MR; Laugher SJ; Kendall MJ; Wise R; Andrews J. (1985). A clinical and pharmacokinetic study of ciprofloxacin administered chronically as i.v. bolus doses to young healthy volunteers. Recent Advances in Chemotherapy. 1587-1588.
  • Franklyn JA; Wilkins MR; Wilkinson R; Ramsden DB; Sheppard MC. (1985). The effect of propranolol on circulating thyroid hormone measurements in thyrotoxic and euthyroid subjects. 108:351-355. DOI.
  • Wilkins MR; Woods KL; Jack DB; Kendall MJ; Laugher SJ. (1985). Separate and combined effects of nadolol and nifedipine on the cardiac response to exercise. European Journal of Clinical Pharmacology. 28:113-117.
  • Zaman R; Kendall MJ; Wilkins MR; Jack DB. (1985). Effect of liver disease on the pharmacokinetics of acebutolol and diacetolol. Biopharmaceutics and Drug Disposition. 6:131-137.
  • Wilkins MR; Franklyn JA; Woods KL; Kendall MJ. (1985). Effect of propranolol on thyroid homeostasis of healthy volunteers. Postgraduate Medical Journal. 61:391-395.
  • Weissberg PJ; West MJ; Wilkins MR; Kricka LJ. (Dec 1984). Effects of changes in dietary sodium intake in normotensive subjects with and without a genetic predisposition to essential hypertension. Journal of Hypertension. 2:511-513.
  • Zaman R; Wilkins MR; Kendall MJ; Jack DB. (1984). The effect of food and alcohol on the pharmacokinetics of acebutolol and its metabolite diacetolol. Biopharmaceutics and Drug Disposition. 5:91-95.
  • Kendall MJ; Woods KL; Wilkins MR. (1982). Responsiveness to beta adrenergic stimulation: the effects of age are cardioselective. British Journal of Clinical Pharmacology. 14:821-826.

Conferences

  • Khoo J; Zhao L; Alp NJ; Bendall J; Nicoli T; Wilkins MR; Channon KM. Tetrahydrobiopterin deficiency causes pulmonary hypertension: Effects on lung superoxide levels, hypoxic pulmonary vasoconstriction and vascular remodelling. Annual Conference of the British-Cardiac-Society. 90:A44-A44. (May 2004).
Share this on DeliciousTweet thisDigg thisStumble thisShare this on Facebook